BTK and B-cell chronic lymphocytic leukemia: Notably, ibrutinib-resistant CLL lymphocytes were re-sensitized to ibrutinib by the combination of a fatty acid metabolism inhibitor and ibrutinib in vitro, confirming the connection of BTK signaling and fatty acid metabolism regulation3.